)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Kyowa Kirin
Kyowa Kirin (4151) investor relations material
Kyowa Kirin Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary2 Nov, 2026
Executive summary
9M 2026 revenue rose 10.2% YoY to ¥384.9bn; core operating profit increased 46.8% to ¥97.0bn and profit rose 58.5% to ¥51.7bn.
Growth was led by global strategic products and technology out-licensing; FX supported reported revenue by ¥19.8bn and core operating profit by ¥8.5bn.
FY 2026 forecasts remained unchanged at revenue of ¥520.0bn, core operating profit of ¥130.0bn and profit of ¥75.0bn.
Financial highlights
Gross profit increased to ¥288.4bn from ¥259.4bn; core operating profit rose to ¥97.0bn from ¥66.1bn on higher gross profit and lower R&D costs despite higher SG&A.
Profit attributable to owners rose to ¥51.7bn from ¥32.6bn; profit before tax was ¥64.7bn versus ¥47.9bn.
Profit included ¥20.2bn in rocatinlimab trial-closing costs and ¥5.0bn in related impairment losses; other impacts included ¥9.4bn in early-retirement costs and a ¥4.3bn established-medicines JV divestment gain.
Other expenses increased to ¥30.9bn from ¥14.7bn, including contract-loss and impairment charges.
Outlook and guidance
FY 2026 forecast: revenue ¥520.0bn (+4.7%), core operating profit ¥130.0bn (+18.4%), profit before tax ¥95.0bn (+8.9%) and profit ¥75.0bn (+11.9%); forecasts unchanged from May 7.
9M progress against the revised FY plan was 74% for revenue, 75% for core operating profit and 69% for profit; favorable FX may support results above plan, but guidance was unchanged.
Libmeldy/Lenmeldy revenue grew 65.6% in 9M; outlook targets 30–40% CAGR over the next three years, supported by newborn screening and geographic expansion.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Kyowa Kirin
- A research failure revealed defucosylation, turning ADCC into a proprietary discovery platform.4151
Corporate presentation - Common-light-chain design pairs bispecific targeting with IgG-like productivity and manufacturability.4151Corporate presentation
- KHK4951 eye drops maintained vision in most nAMD patients, showing promise for less invasive therapy.4151Investor presentation
- Double-digit revenue and profit growth driven by global product demand and tech-licensing.4151Q2 2026
- Revenue and profit soared on global growth, tech-licensing, and raised profit guidance.4151Q1 2026
- Record FY2025 revenue and profit, with FY2026 guided for higher sales but lower core margin.4151Q4 2025
- Kyowa Kirin takes full control of rocatinlimab, aiming for 2026 regulatory submissions and strong market growth.4151Investor presentation
- Revenue and profit fell, but overseas growth and pipeline progress remained strong.4151Q2 2025
- Global partnership accelerates ziftomenib's development with major financial and operational backing.4151Collaboration
Next Kyowa Kirin earnings date
Q4 20265 Feb, 2027
Kyowa Kirin
Next Kyowa Kirin earnings date
Q4 20265 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Kyowa Kirin Co., Ltd. is a Japanese pharmaceutical company engaged in the research, development, manufacturing, and marketing of biopharmaceutical and pharmaceutical products. The company focuses on therapeutic areas including oncology, nephrology, immunology, and the central nervous system, aiming to address complex medical needs. Kyowa Kirin leverages biotechnology and antibody research to develop treatments for patients globally, with products available through prescription channels and hospital networks. The company is headquartered in Tokyo, Japan, and its shares are listed on the TSE.